Desloratadine: A preclinical and clinical overview

Drugs of Today

Volumn 37, Issue 4, 2001, Pages 215-227

  Norman, P ^a   Dihlmann, A ^a   Rabasseda, X ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYDESLORATADINE; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOCHROME P450 INHIBITOR; DESLORATADINE; ERYTHROMYCIN; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; LORATADINE; PLACEBO; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NOSE CONGESTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; URTICARIA;

EID: 0034982603     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.4.620586     Document Type: Review

References (47)

1. The effect of IL-4 on human nasal mucosal responses
2. Physiologic responses to intranasal doseresponse challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy
3. Desloratadine
4. 1 receptor antagonist. 1st communication: Receptor selectivity, antihistaminic effects and antiallergenic effects
5. 2+ levels and leukotriene release: Novel mechanisms of action independent of the anti-histamine activity
6. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma
7. In vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3)
8. Inhibition of cytokine generation and mediator release in human basophils by desloratadine
9. 1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines
10. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells
11. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human FcεRI+ cells
12. Loratadine (L) reduces RANTES release by an epithelial cell line
13. Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation
14. Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle
15. 1 receptor
16. 1 receptor
17. Dose-proportionality, linearity, and pharmacokinetics of desloratadine in healthy adults
18. Multiple-dose pharmacokinetics, safety, and tolerance of desloratadine in healthy volunteers
19. Multiple-dose pharmacokinetics of desloratadine in subjects differing in race and gender
20. The effect of food on the oral biovailability of desloratadine
21. Therapeutic advantages of third generation antihistamines
22. Desloratadine and ketoconazole: Pharmacokinetics and electrocardiographic pharmacodynamic effects
23. Desloratadine and erythromycin: Pharmacokinetics and electrocardiographic pharmacodynamic effects
24. Rapid onset of action of desloratadine in patients with seasonal allergic rhinitis
25. Efficacy and safety of desloratadine in seasonal allergic rhinitis
26. Desloratadine is effective at relieving nasal congestion, as demonstrated in three placebo-controlled trials in patients with seasonal allergic rhinitis
27. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis
28. Onset and duration of action of desloratadine
29. Desloratadine improves quality of life in patients with seasonal allergic rhinitis
30. Long-term benefit of desloratadine against seasonal allergic rhinitis symptoms in patients with asthma
31. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis and asthma
32. Desloratadine reduces seasonal allergic rhinitis symptoms in patients with seasonal allergic rhinitis and asthma
33. 2-agonists and improves asthma symptoms in patients with seasonal allergic rhinitis and asthma
34. Allergic rhinitis and asthma: How important is the link?
35. Nasal obstruction as a risk factor for sleep-disordered breathing
36. Airway cooling in asthmatic and nonasthmatic subjects during nasal and oral breathing
37. Desloratadine in the treatment of chronic idiopathic urticaria
38. Electrocardiographic effects of multiple high doses of desloratadine
39. Comparative effects of desloratadine and placebo with and without alcohol on performance measures
40. Effect of descarboethoxyloratadine, the major metabolite of loratadine, on the human cardiac potassium channel Kv1.5
41. Unlike fexofenadine, the pharmacokinetics of desloratadine are minimally altered by coadministration with azithromycin
42. No drug interaction between fluoxetine and desloratadine, a new nonsedating once-daily anti-histamine
43. Desloratadine has no effect on wakefulness or psychomotor performance
44. Desloratadine does not impair actual driving performance: A 3-way crossover comparison with diphenhydramine and placebo
45. 1 receptor antagonist. 2nd communication: Lack of central nervous system and cardiovascular effects
46. The pharmacologic profile of desloratadine: A review
47. 1 receptor antagonists